AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32372561 — intervention group
Group type: COMPARATOR
Intervention: Oral methylcobalamin tablet and lidocaine local injection (OM group)
Number of subjects: 105
Study 35441412 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 878
Study 35441412 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 878
Study 35441412 — intervention group
Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 878
Study 33959583 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare clown intervention (IG)
Number of subjects: 62
Study 33959583 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (CG)
Number of subjects: 62
Study 32902375 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus invasive urodynamics (UDS)
Number of subjects: 820
Study 32902375 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 820
Study 32826829 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-ice high-intensity training (HIT) shock microcycle
Number of subjects: 14
Study 32826829 — intervention group
Group type: COMPARATOR
Intervention: Usual pre-season training (control)
Number of subjects: 14
Study 33137599 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg three times daily)
Number of subjects: 72
Study 33137599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 36036496 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing (nuclear stress testing, exercise electrocardiography, or stress echocardiography)
Number of subjects: 1706
Study 36036496 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1706
Study 36036496 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 1706
Study 34391443 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached sites (n=6)
Number of subjects: 12
Study 34391443 — intervention group
Group type: COMPARATOR
Intervention: Non-coached sites (n=6)
Number of subjects: 12
Study 34391443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both coached and non-coached sites
Number of subjects: 12
Study 35960095 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (n = 242)
Number of subjects: 472
Study 35960095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 230)
Number of subjects: 472
Study 34789239 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT clinical pathway (CP) for screening and management of anxiety and depression
Number of subjects: 106
Study 34789239 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT clinical pathway (CP)
Number of subjects: 106
Study 32949370 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg post-5-min intravenous infusion
Number of subjects: 9
Study 32949370 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 1500 mg post-15-min intravenous infusion
Number of subjects: 9
Study 32949370 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (LEV) 1500 mg post-15-min intravenous infusion
Number of subjects: 9
Study 32949370 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (LEV) 1500 mg post-5-min intravenous infusion
Number of subjects: 9
Study 32949370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data for BRV and LEV
Number of subjects: 9
Study 35090638 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722
Study 35090638 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722
Study 35090638 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 7mu;g CoV2 preS dTM with AS03
Number of subjects: 722
Study 32976844 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor swing and stance controlled knee‐ankle‐foot orthosis (MPO)
Number of subjects: 18
Study 35279201 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF)
Number of subjects: 126
Study 35279201 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 126
Study 32873466 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐0 knotless barbed suture (polydioxanone)
Number of subjects: 25
Study 32873466 — intervention group
Group type: COMPARATOR
Intervention: 4‐0 polyglactin 910 (vicryl)
Number of subjects: 25
Study 34181362 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 12
Study 34181362 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 12
Study 34181362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35101085 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 6 months
Number of subjects: 30
Study 35101085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33040590 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for rehabilitation
Number of subjects: 101
Study 33040590 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 101
Study 34047794 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted mean duration of response (DOR)
Number of subjects: 1376
Study 34047794 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted mean DOR
Number of subjects: 1376
Study 34047794 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 1376
Study 34047794 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective response rate (ORR)
Number of subjects: 1376
Study 616065144 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nurse-led home health care visit after discharge
Number of subjects: 1500
Study 33991330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 33991330 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 90
Study 34078324 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Treatment (SET)
Number of subjects: 124
Study 34078324 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Treatment (EFT)
Number of subjects: 124
Study 34078324 — intervention group
Group type: COMPARATOR
Intervention: SET and EFT
Number of subjects: 124
Study 32353218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (resistance and aerobic) 3 days/week for 60 minutes
Number of subjects: 53
Study 32353218 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical orientations
Number of subjects: 53
Study 35238397 — intervention group
Group type: EXPERIMENTAL
Intervention: CJR model
Number of subjects: 17447
Study 35238397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17447
Study 32751522 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (500 mg/day)
Number of subjects: 52
Study 33656950 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery with postoperative physical therapy (SPT)
Number of subjects: 90
Study 33656950 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone (PTA)
Number of subjects: 90
Study 35029879 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR therapy
Number of subjects: 0
Study 35029879 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 32501761 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoFlex TLC Calamine
Number of subjects: 39
Study 32501761 — intervention group
Group type: COMPARATOR
Intervention: Coban2
Number of subjects: 39
Study 33829499 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered intervention (ODI)
Number of subjects: 334
Study 33829499 — intervention group
Group type: COMPARATOR
Intervention: Staff-delivered intervention (SDI)
Number of subjects: 334
Study 33346782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor added to aspirin
Number of subjects: 0
Study 33346782 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 36069630 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched pain management (EPM) pathway integrating physical therapy and mindfulness
Number of subjects: 0
Study 36069630 — intervention group
Group type: COMPARATOR
Intervention: Usual care pain management (UC)
Number of subjects: 0
Study 32703548 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (haemoglobin, 90–110 g L−1)
Number of subjects: 200
Study 32703548 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (haemoglobin, 70–90 g L−1)
Number of subjects: 200
Study 32703548 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 200
Study 32703548 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 200
Study 35981755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 0
Study 32985946 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3-mg/kg bodyweight)
Number of subjects: 0
Study 32985946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3-mg/kg bodyweight lactose)
Number of subjects: 0
Study 32853821 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Symptom Index (ASI)
Number of subjects: 1218
Study 32853821 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Symptom Utility Index (ASUI)
Number of subjects: 1218
Study 32853821 — intervention group
Group type: COMPARATOR
Intervention: Asthma Control Questionnaire (ACQ-5)
Number of subjects: 1218
Study 32853821 — intervention group
Group type: COMPARATOR
Intervention: St George's Respiratory Questionnaire (SGRQ)
Number of subjects: 1218
Study 32719000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus (CMV)-specific dendritic cell (DC) vaccines
Number of subjects: 200
Study 35779909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 40
Study 35779909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33604869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 1322
Study 33604869 — intervention group
Group type: COMPARATOR
Intervention: Non-Surgical (NS)
Number of subjects: 1322
Study 33604869 — intervention group
Group type: COMPARATOR
Intervention: General Population (GP)
Number of subjects: 1322
Study 36389329 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSight double-lumen tube
Number of subjects: 71
Study 36389329 — intervention group
Group type: COMPARATOR
Intervention: Standard double-lumen tube (DLT)
Number of subjects: 71
Study 32586395 — intervention group
Group type: EXPERIMENTAL
Intervention: gammaCore®-Sapphire device plus standard of care
Number of subjects: 90
Study 32586395 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone (SoC)
Number of subjects: 90
Study 33922323 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope flap (EF)
Number of subjects: 60
Study 33922323 — intervention group
Group type: COMPARATOR
Intervention: Szmyd flap (SF)
Number of subjects: 60
Study 33922323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EF and SF
Number of subjects: 60
Study 32951360 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended systolic blood pressure measurement
Number of subjects: 102
Study 32951360 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended systolic blood pressure measurement
Number of subjects: 102
Study 32951360 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic systolic blood pressure measurement
Number of subjects: 102
Study 32951360 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of attended vs unattended SBP
Number of subjects: 102
Study 32951360 — intervention group
Group type: COMPARATOR
Intervention: Comparison of routine clinic SBP vs attended SBP
Number of subjects: 102
Study 32951360 — intervention group
Group type: COMPARATOR
Intervention: Comparison of routine clinic SBP vs unattended SBP
Number of subjects: 102
Study 35331810 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI QFR assessment in patients with diabetes mellitus (DM)
Number of subjects: 2227
Study 35331810 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI QFR assessment in patients without diabetes (non-DM)
Number of subjects: 2227
Study 35331810 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI QFR results (≤0.92) in patients with diabetes mellitus (DM)
Number of subjects: 2227
Study 35331810 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI QFR results (≤0.92) in patients without diabetes (non-DM)
Number of subjects: 2227
Study 33567336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 45
Study 33567336 — intervention group
Group type: COMPARATOR
Intervention: Sham Dry Needling
Number of subjects: 45
Study 33567336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 32469183 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix (120 mg orally once daily)
Number of subjects: 930
Study 32469183 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (injections every 3 months)
Number of subjects: 930
Study 32469183 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix
Number of subjects: 930
Study 32469183 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 930
Study 34908015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iron formula with added bovine lactoferrin (1.0 g/L)
Number of subjects: 180
Study 34908015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iron formula with no added lactoferrin
Number of subjects: 180
Study 34908015 — intervention group
Group type: COMPARATOR
Intervention: Standard formula at 8 mg/L iron and no added lactoferrin (control formula)
Number of subjects: 180
Study 33198761 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-ARS
Number of subjects: 34
Study 33198761 — intervention group
Group type: COMPARATOR
Intervention: Traditional presentation (Control Group)
Number of subjects: 34
Study 34182833 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific injury prevention neuromuscular training programme (SIPP)
Number of subjects: 14
Study 34182833 — intervention group
Group type: COMPARATOR
Intervention: Active general control (GIPP)
Number of subjects: 14
Study 34080821 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoid artery ligation with suture mucopexy (DGHAL-SM)
Number of subjects: 80
Study 34080821 — intervention group
Group type: COMPARATOR
Intervention: LigaSure™-assisted pile excision (LAP)
Number of subjects: 80
Study 36270673 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion program (intervention group)
Number of subjects: 43
Study 36270673 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 43
Study 34446483 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention with integrated skin screening and SDR-PEP administration
Number of subjects: 100
Study 34446483 — intervention group
Group type: COMPARATOR
Intervention: Health centre-based intervention with integrated skin screening and SDR-PEP administration
Number of subjects: 100
Study 32408862 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC D-Blade videolaryngoscope
Number of subjects: 95
Study 32408862 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 95
Study 35398627 — intervention group
Group type: EXPERIMENTAL
Intervention: Light + Caffeine
Number of subjects: 30
Study 35398627 — intervention group
Group type: EXPERIMENTAL
Intervention: Light
Number of subjects: 30
Study 35398627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30
Study 35398627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with low ELISA optical density (OD) values (0.4-1)
Number of subjects: 38
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with intermediate ELISA OD values (>1-2.5)
Number of subjects: 38
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with high ELISA OD values (>2.5)
Number of subjects: 38
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with low 4T score
Number of subjects: 38
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with intermediate 4T score
Number of subjects: 38
Study 33085589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera with high 4T score
Number of subjects: 38
Study 36199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation combined with anti-PD-1 monoclonal antibody
Number of subjects: 122
Study 36199771 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Number of subjects: 122
Study 33533898 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection (n = 1196)
Number of subjects: 1399
Study 33533898 — intervention group
Group type: COMPARATOR
Intervention: Final R1 resections (n = 131)
Number of subjects: 1399
Study 33533898 — intervention group
Group type: COMPARATOR
Intervention: Margin conversion from IONM-positive to R0 resection (n = 72)
Number of subjects: 1399
Study 35939520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention (improved latrines, sani-scoops, children's potties, in-person behavioral promotion)
Number of subjects: 720
Study 35939520 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no sanitation intervention)
Number of subjects: 720
Study 35939520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention
Number of subjects: 720
Study 35939520 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 720
Study 33607060 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi or ARB treatment (n=3601)
Number of subjects: 9365
Study 33607060 — intervention group
Group type: COMPARATOR
Intervention: No ACEi or ARB treatment (n=3601)
Number of subjects: 9365
Study 35655178 — intervention group
Group type: EXPERIMENTAL
Intervention: Workstation intervention
Number of subjects: 60
Study 35655178 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study 32126990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICMA (intracameral combination of 2 mydriatics and 1 anesthetic)
Number of subjects: 57
Study 32126990 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen (conventional treatment)
Number of subjects: 57
Study 32126990 — intervention group
Group type: EXPERIMENTAL
Intervention: ICMA
Number of subjects: 57
Study 32126990 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen
Number of subjects: 57
Study 35642684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's Sonata
Number of subjects: 70
Study 35642684 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 70
Study 35642684 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 70
Study 33216815 — intervention group
Group type: EXPERIMENTAL
Intervention: Free water elimination
Number of subjects: 68
Study 33216815 — intervention group
Group type: EXPERIMENTAL
Intervention: Free water content and mean diffusivity measured along the cingulum
Number of subjects: 68
Study 34850368 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fasting conditions
Number of subjects: 48
Study 34850368 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (JANUMET®) under fasting conditions
Number of subjects: 48
Study 34850368 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of sitagliptin phosphate/metformin hydrochloride tablets (50 mg/850 mg) under fed conditions
Number of subjects: 48
Study 34850368 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (JANUMET®) under fed conditions
Number of subjects: 48
Study 33096550 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 oz-equivalent/d of protein foods
Number of subjects: 51
Study 33096550 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 oz-equivalent/d of protein foods
Number of subjects: 51
Study 33096550 — intervention group
Group type: COMPARATOR
Intervention: Both protein intake groups (5 oz and 12.5 oz)
Number of subjects: 51
Study 35480507 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia (DN)
Number of subjects: 80
Study 35480507 — intervention group
Group type: COMPARATOR
Intervention: Saint Thomas cardioplegia (ST)
Number of subjects: 80
Study 36055332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (1080 mg subcutaneously twice weekly)
Number of subjects: 80
Study 36055332 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab to pegcetacoplan
Number of subjects: 80
Study 36055332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monotherapy
Number of subjects: 80
Study 36055332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan-to-pegcetacoplan
Number of subjects: 80
Study 36055332 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab-to-pegcetacoplan
Number of subjects: 80
Study 36055332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 80
Study 34593587 — intervention group
Group type: EXPERIMENTAL
Intervention: SBCC intervention by community health workers (CHWs)
Number of subjects: 0
Study 34856212 — intervention group
Group type: COMPARATOR
Intervention: CWC with AH Plus sealer
Number of subjects: 74
Study 34856212 — intervention group
Group type: EXPERIMENTAL
Intervention: SBO with Endoseal TCS
Number of subjects: 74
Study 34856212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CWC and SBO)
Number of subjects: 74
Study 34856212 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with sealer extrusion
Number of subjects: 74
Study 33211326 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (MLE)
Number of subjects: 128
Study 33211326 — intervention group
Group type: COMPARATOR
Intervention: Soybean-based lipid emulsion (SLE)
Number of subjects: 128
Study 36123153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanden breathing (video-guided, 10 min once a day for 6 weeks)
Number of subjects: 20
Study 36123153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 36123153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanden breathing (intervention group)
Number of subjects: 20